Calcium 2,5-dihydroxybenzenesulfonate (CaD) is considered a vasoprotective drug that alleviates microcirculatory and hemorheological abnormalities (190), attenuates diabetes-induced endothelial dysfunction and inflammation (191, 192), and reduces diabetic vascular complications by interfering with acetyl heparin sulfate binding sites to decrease VEGF signaling (193). Here, VEGFA is linked to diabetes mellitus.